Saba Capital Management, L.P.'s Form 4 filing
abrdn Life Sciences Investors (HQL) · filed Mar 31, 2025
- Accession no.
- 0001510281-25-000174
- Filed
- Mar 31, 2025, 12:07 PM ET
- Trade date
- Mar 27-28, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $475.0K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Saba Capital Management, L.P.CIK 0001510281 | 10% Owner |
| Weinstein BoazCIK 0001608233 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 27, 2025 | Common Stock | SSaleDisposed | −32,922 | $13.01 | −$428,315.22 | 3,240,630 | Indirect | |
| Mar 28, 2025 | Common Stock | SSaleDisposed | −3,602 | $12.95 | −$46,645.9 | 3,237,028 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.